PA
NMRA icon

Profund Advisors’s Neumora Therapeutics NMRA Stock Holding History

Profund Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,383
Closed -$227K – 1069
2024
Q4 		$227K Buy
21,383
+10,555
+97% +$127K 0.01% 938
2024
Q3 		$143K Buy
+10,828
New +$126K 0.01% 1088

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Profund Advisors's NMRA Position: Q1 2025 in Review

Profund Advisors sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 21,383 shares — an estimated $227K sold.

Profund Advisors first reported a position in NMRA in Q3 2024 and held it in 2 quarters. The position peaked at $227K in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Profund Advisors reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Profund Advisors sold 21,383 Neumora Therapeutics shares in Q1 2025, an estimated $227K.
  • Profund Advisors first reported a position in Neumora Therapeutics in Q3 2024 and held it in 2 quarters.
  • Profund Advisors's Neumora Therapeutics position peaked at $227K in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Profund Advisors's 13F filing for Q1 2025, filed 8 May 2025.